A surprise positive opinion from regulators in Europe regarding Encysive Pharmaceuticals Inc.'s Thelin took the sting out of the less happy news from U.S. regulators earlier this year, and Wall Street rewarded the company with a stock boost of about 35 percent. (BioWorld Today)
Continuing a busy year, Applied Biosystems Group entered a deal to buy out Agencourt Personal Genomics Inc. for about $120 million in cash, gaining high-throughput analysis of DNA and RNA to supplement the existing platform. (BioWorld Today)
Despite a somewhat ambivalent vote by its advisory panel, the FDA approved a label expansion for Cubist Pharmaceuticals Inc.'s antibiotic Cubicin (daptomycin), which now can be used against infections in the bloodstream and heart valves, as well as skin. (BioWorld Today)
